This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234–4242.
Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548–4554.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791–1799.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805–811.
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ⩾4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25: 1622–1628.
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203–212.
Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V . Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000; 11: 1105–1114.
Wongso D, Fuchs M, Plutschow A, Klimm B, Sasse S, Hertenstein B et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin study group. J Clin Oncol 2013; 31: 2819–2824.
Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ⩾3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016; 34: 2028–2036.
Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943–952.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a Study by Fondazione Italiana Linfomi. J Clin Oncol 2016; 34: 1175–1181.
Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980–5987.
Acknowledgements
We are indebted to Drs Lugtenburg (EORTC), Jaubert (LYSA), Blanc (LYSA), Pignon (LYSA), Eisenmann (LYSA), Gonzales (LYSA), Kernels (LYSA), Devidas (LYSA), Helias (LYSA), Thyss (LYSA), Christian (LYSA), Coiffier (LYSA), Bron (EORTC), Castaigne (LYSA), Eghbali (LYSA), Baars (EORTC), Fitoussi (LYSA), Raemaekers (EORTC) and Van Imhoff (EORTC), who contributed to this research. We also thank the EORTC Headquarters team, in particular, Bart Meulemans and Alice Preumont. This publication was supported by Fonds Cancer (FOCA) from Belgium.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ghez, D., Fortpied, C., Mounier, N. et al. First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma. Bone Marrow Transplant 52, 310–312 (2017). https://doi.org/10.1038/bmt.2016.271
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.271